“The research and production center of the FMBA of Russia, taking into account the Chinese and French experience, has developed a treatment regimen for coronavirus infection based on the antimalarial drug mefloquine,” the press service noted.
“The drug with high selectivity blocks the cytopathic effect of the coronavirus in cell culture and prevents its replication, and the immunosuppressive effect of mefloquine prevents the activation of the inflammatory response caused by the virus. The addition of macrolide antibiotics and synthetic penicillin not only prevents the formation of a secondary bacterial-viral syndrome but also increases the concentration of antiviral agents in the blood plasma and lungs. This will ensure effective treatment of patients with various degrees of coronavirus infection,” said Veronika Skvortsova, head of the FMBA of Russia.
This will ensure the effective treatment of patients with COVID-19 of varying severity.
Also, based on mefloquine, an effective and safe scheme for the prevention of coronavirus infection is being developed.